Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics' partner, Pierre Fabre Pharmaceuticals, has received FDA acceptance for the resubmission of the Biologics License Application (BLA) for tabelecleucel, aimed at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients aged two years and older. The BLA is classified as a Class 2 Resubmission, with a target action date set for March 31, 2027.